ImmunoGen, Inc.

ImmunoGen, Inc. is a biotechnology company specializing in the development of antibody-drug conjugates (ADCs) for the treatment of cancer. Their mission is to disrupt the progression of cancer and improve the lives of patients by creating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles. The company has a robust pipeline of ADCs targeting solid tumors and hematologic malignancies, with their lead product, Mirvetuximab Soravtansine-gynx (ELAHERE™), receiving accelerated approval from the FDA in 2022 for the treatment of ovarian cancer.

ImmunoGen has been at the forefront of ADC research for over four decades, building a reputation for scientific expertise and innovation. They have a deep understanding of the different components of ADCs, including target selection, toxic payloads, antibodies, and linkers. This expertise has led to several successful partnerships with other pharmaceutical companies, including the first-ever ADC approved for HER2-positive breast cancer, Kadcyla®. ImmunoGen continues to develop next-generation ADCs with the goal of providing more good days for cancer patients.

ImmunoGen is a biotechnology company committed to disrupting the progression of cancer and improving outcomes for patients by developing targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles. Their mission is to keep cancer from interrupting patients' lives, allowing them to experience more good days. Their focus on developing the most precise, targeted cancer therapies, specifically antibody-drug conjugates (ADCs), drives their commitment to “target a better now” for cancer patients.

ImmunoGen promotes a culture of collaboration, innovation, and unwavering dedication to improving the lives of cancer patients. They encourage a sense of shared responsibility and celebrate successes as a team. The company prioritizes making progress with purpose, ensuring that their efforts directly benefit patients and lead to a better now.

ImmunoGen, Inc. is committed to fostering a diverse, equitable, and inclusive workplace where all employees feel valued, respected, and empowered to contribute their unique perspectives. The company believes that a diverse workforce leads to better decision-making, innovation, and overall success. ImmunoGen actively promotes diversity and inclusion through various initiatives, including recruitment and retention programs, employee resource groups, and leadership development programs. The company is dedicated to creating a culture where every employee feels a sense of belonging and has equal opportunities for growth and advancement.